The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Alteration to Loan Notes

11 Dec 2008 16:31

Cubus Lux plc ("Cubus Lux" or the "Company") Alteration to Loan Notes

Cubus Lux, the Croatia-focused leisure resort operator and developer, announces that it has agreed to change the terms of the loan notes issued in consideration for the acquisition of the Olive Island Resort companies as set out herein.

In February 2008, Cubus Lux acquired companies which own the Olive Island Resort development project in consideration for which they issued ¢â€š¬13 million of loan notes (the "Loan Notes") and ¢â€š¬14.45 million of ordinary shares in the Company to the vendors (who included three directors of Cubus Lux: Gerhard Huber, Christian Kaiser and Michael Janssen). Details of this transaction were set out in an admission document published on 15 January 2008.

Under the documentation constituting the Loan Notes, the holders of the Loan Notes had, during a 10 business day period commencing on 22 November 2008, the right to require the Company to redeem the Loan Notes by giving three months notice, at 103 per cent. of the par value.

The acquisition agreement by which the Olive Island companies were acquired included a condition subsequent whereby until good title to, or a constituted construction right over, the Olive Island land is granted, then the acquisition can be required to be unwound.

Although good progress is being made by Cubus Lux towards acquiring full title and construction rights over the land, this has not yet been legally granted. Therefore, had the Loan Note holders required the Company to redeem the Loan Notes, the Company would have had no choice but to unwind the acquisition agreement. The Board and Loan Note holders agreed that this was in the interest of neither the Company nor the Loan Note holders. Accordingly the Company and the Loan Note holders have agreed that in consideration for the Loan Note holders not issuing a notice requiring the redemption of the Loan Notes, the Company would permit the Loan Note holders to require redemption on 31 December 2009, by giving three months' notice.

Since three of the Loan Note holders (Gerhard Huber, Christian Kaiser and Michael Janssen) are directors of Cubus Lux, this extension constitutes a related party transaction as defined in the AIM Rules for Companies. Where a company whose shares are quoted on AIM enters into such a transaction, the requirement is for those directors of the company who are independent of the transaction to consider, after consultation with the company's nominated adviser, whether the terms of the transaction are fair and reasonable insofar as the company's shareholders are concerned.

The independent directors (being all of the directors with the exception of Gerhard Huber, Christian Kaiser and Michael Janssen), having consulted with Dowgate Capital Advisers Limited, consider that the changes to the terms of the Loan Notes are fair and reasonable insofar as the shareholders of the Company are concerned.

For further information please see www.cubuslux.com or contact:

Steve McCannCubus Lux plc+385 (0)99 214 9636Simon Sacerdoti/Liam Murray, Nominated AdviserDowgate Capital Advisers Limited+44 (0)20 7492 4777Claire Louise Noyce/Stephen Austin, BrokerHybridan LLP+44 (0)20 3159 5085Pam SpoonerCity Road Communications+44 (0) 20 7248 8010+44 (0)7858 477 747

vendor
Date   Source Headline
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 202211:00 amRNSPrice Monitoring Extension
22nd Mar 20227:00 amRNSDirectorate change
14th Mar 20224:41 pmRNSSecond Price Monitoring Extn
14th Mar 20224:36 pmRNSPrice Monitoring Extension
14th Mar 20222:05 pmRNSSecond Price Monitoring Extn
14th Mar 20222:00 pmRNSPrice Monitoring Extension
14th Mar 20227:00 amRNSLaunch of outdoor marketing campaign
8th Mar 202211:03 amRNSShare purchase by CEO
7th Mar 202211:05 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
4th Mar 20224:41 pmRNSSecond Price Monitoring Extn
4th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSExercise of Warrants
1st Mar 20227:00 amRNSLaunch of Rejuvenating Cannabinoid Face Serum
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
23rd Feb 20222:06 pmRNSSecond Price Monitoring Extn
23rd Feb 20222:01 pmRNSPrice Monitoring Extension
21st Feb 202211:05 amRNSSecond Price Monitoring Extn
21st Feb 202211:00 amRNSPrice Monitoring Extension
21st Feb 20229:05 amRNSSecond Price Monitoring Extn
21st Feb 20229:00 amRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSStrategy and trading update
2nd Feb 20227:00 amRNSWhite paper on cannabinoids and skin aging
7th Jan 20221:00 pmRNSResults of Annual General Meeting
15th Dec 20217:00 amRNSAnnual General Meeting update
8th Dec 20217:00 amRNSGrant of Options to CEO
6th Dec 20211:57 pmRNSPosting of Annual Report and Notice of AGM
6th Dec 20217:00 amRNSAppointment of new CEO
3rd Dec 20217:00 amRNSAnnual results
1st Dec 20217:00 amRNSLaunch of inaugural products & ecommerce platform
11th Nov 20217:00 amRNSAdvertising and PR agencies appointed
8th Nov 20212:05 pmRNSSecond Price Monitoring Extn
8th Nov 20212:00 pmRNSPrice Monitoring Extension
8th Nov 202111:05 amRNSSecond Price Monitoring Extn
8th Nov 202111:00 amRNSPrice Monitoring Extension
1st Nov 20217:00 amRNSGrant of Share Options and update on warrants
4th Oct 20219:06 amRNSSecond Price Monitoring Extn
4th Oct 20219:00 amRNSPrice Monitoring Extension
4th Oct 20217:00 amRNSDirector dealings & TR1 notification
16th Aug 20217:00 amRNSSupply agreement signed with Chanelle McCoy Health
2nd Aug 20217:00 amRNSShare disposal by significant shareholder
28th Jul 20212:06 pmRNSSecond Price Monitoring Extn
28th Jul 20212:00 pmRNSPrice Monitoring Extension
10th Jun 20217:00 amRNSSupply agreement signed with Willow Biosciences
25th May 20217:00 amRNSCellular Goods Interim Results
6th May 20217:00 amRNSGrant of Warrants and Extension of Exercise Period
20th Apr 20212:00 pmRNSPrice Monitoring Extension
12th Apr 20217:00 amRNSCellular Goods boosts team with five appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.